Scientific report 2024 of the Cellular Therapy and Immunobiology Working Party (CTIWP)

The CTIWP is growing in line with the increasing application of cell therapy in different diseases. 

The collaboration with the different working parties and partner society (GoCART, EHA) is ongoing with the aim to harmonise the practice and the workload in the cell therapy field. Communication and regular meetings with the stakeholders are in place to ensure the high quality of researches.

The research activity of the CTIWP is wide and focus on different factors associated with transplant outcomes (immunogenetics and conditioning regimens), as well with CAR T cell therapy. In particular, the fertility after CAR T is being investigated, and the use of CAR T in patients with autoimmune disease, as primary or concomitant disease. This study will open new insight in the application of CAR T in non-malignant diseases. 

Another important ongoing evaluation is the outcomes of CAR T cell therapies in older patients who are frail, focusing on toxicities and long term results.